Your browser doesn't support javascript.
loading
Oral bioavailability and disposition characteristics of irbesartan, an angiotensin antagonist, in healthy volunteers.
Vachharajani, N N; Shyu, W C; Chando, T J; Everett, D W; Greene, D S; Barbhaiya, R H.
Affiliation
  • Vachharajani NN; Department of Metabolism and Pharmacokinetics, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08540, USA.
J Clin Pharmacol ; 38(8): 702-7, 1998 Aug.
Article in En | MEDLINE | ID: mdl-9725545
ABSTRACT
Absolute oral bioavailability and disposition characteristics of irbesartan, an angiotensin II receptor antagonist, were investigated in 18 healthy young male volunteers. Subjects received [14C] irbesartan as a 30-minute intravenous infusion (50 mg), [14C] irbesartan orally as a solution (50 mg or 150 mg), or irbesartan capsule (50 mg). Irbesartan was rapidly and almost completely absorbed after oral administration, and exhibited a mean absolute oral bioavailability of 60% to 80%. Mean total body clearance was approximately 157 mL/min, and renal clearance was 3.0 mL/min. Volume of distribution at steady state was 53 L to 93 L, and terminal elimination half-life was approximately 13 to 16 hours. Hepatic extraction ratio was low (0.2). There were no major circulating metabolites, and approximately 80% of total plasma radioactivity was attributable to unchanged irbesartan. Regardless of route of administration, approximately 20% of dose was recovered in urine and the remainder in feces.
Subject(s)
Search on Google
Collection: 01-internacional Database: MEDLINE Main subject: Tetrazoles / Biphenyl Compounds / Angiotensin II / Angiotensin Receptor Antagonists Type of study: Clinical_trials / Prognostic_studies Limits: Adult / Humans / Male Language: En Journal: J Clin Pharmacol Year: 1998 Document type: Article Affiliation country: United States
Search on Google
Collection: 01-internacional Database: MEDLINE Main subject: Tetrazoles / Biphenyl Compounds / Angiotensin II / Angiotensin Receptor Antagonists Type of study: Clinical_trials / Prognostic_studies Limits: Adult / Humans / Male Language: En Journal: J Clin Pharmacol Year: 1998 Document type: Article Affiliation country: United States